Swiss Pharmaceuticals & Biotech Big Green Snowflakes

Roche Holding

Market Cap: CHF 299.7b

Engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand.

Bachem Holding

Market Cap: CHF 5.8b

Provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide.

Tecan Group

Market Cap: CHF 2.4b

Provides laboratory instruments and solutions in biopharmaceuticals, forensics, and clinical diagnostics in Europe, North America, Asia, and internationally.

MindMaze Therapeutics Holding

Market Cap: CHF 29.0m

Operates as a commercial-stage biopharmaceutical and neurotechnology company in Asia, the United States, Switzerland, rest of Europe, and internationally.

SKAN Group

Market Cap: CHF 1.5b

Provides isolators, cleanroom devices, and decontamination processes for pharmaceutical and chemical industries in Europe, the Americas, Asia, and internationally.

Kuros Biosciences

Market Cap: CHF 853.7m

Engages in the commercialization and development of biologic technologies for musculoskeletal care in the United States of America, the European Union, and internationally.

Novartis

Market Cap: CHF 242.2b

Researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally.

Lonza Group

Market Cap: CHF 41.4b

Operates as a contract development and manufacturing organization for pharma and biotech companies in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally.

Cosmo

Market Cap: CHF 991.9m

A life sciences company, develops and manufactures pharmaceuticals and contracts for gastroenterology, dermatology, and health tech in Ireland and internationally.

Galderma Group

Market Cap: CHF 40.0b

Operates as a dermatology company worldwide.

Basilea Pharmaceutica

Market Cap: CHF 801.2m

A Swiss commercial-stage biotech company focused on developing and commercializing treatments for severe bacterial and fungal infections.

Siegfried Holding

Market Cap: CHF 3.5b

Engages in contract development and manufacturing of active pharmaceutical ingredient (API) and finished dosage forms worldwide.

Sandoz Group

Market Cap: CHF 32.0b

Develops, manufactures, and markets generic and biosimilars worldwide.

Newron Pharmaceuticals

Market Cap: CHF 260.9m

A biopharmaceutical company, discovers and develops novel therapies for patients with diseases of the central and peripheral nervous system in Italy and the United States.

Dottikon ES Holding

Market Cap: CHF 3.8b

Manufactures and sells performance chemicals, intermediates, and active pharmaceutical ingredients for the chemical, biotech, and pharmaceutical industries.

Molecular Partners

Market Cap: CHF 130.9m

A clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland.

Idorsia

Market Cap: CHF 1.5b

A biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for unmet medical needs in Switzerland, the United States, Japan, Europe, China, and Canada.

PolyPeptide Group

Market Cap: CHF 1.5b

Operates as a contract development and manufacturing company in Europe, the United States, Asia Pacific, and internationally.

BioVersys

Market Cap: CHF 145.5m

Researches and develops antimicrobial drugs for bacterial infections.

Santhera Pharmaceuticals Holding

Market Cap: CHF 253.7m

A specialty pharmaceutical company, together with its subsidiaries, develops and sells medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the Europe, North America, and Asia.

Addex Therapeutics

Market Cap: CHF 4.2m

Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for neurological disorders in Switzerland.

Xlife Sciences

Market Cap: CHF 86.7m

Focuses on the development and commercialization of research projects in the life sciences sector.

Curatis Holding

Market Cap: CHF 103.4m

Engages in the acquisition, development, and commercialization of medicines for the prevention, diagnosis, and treatment of rare and specialty care diseases.